China Universal Asset Management Company’s Monte Rosa Therapeutics GLUE Stock Holding History

China Universal Asset Management Company’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Buy	15,045 +1,515	+11%	+$28.6K	0.02%	292
2026 Q1	$223K	Sell	13,530 -5,081	-27%	-$97.2K	0.02%	344
2025 Q4	$292K	Sell	18,611 -12,214	-40%	-$165K	0.02%	310
2025 Q3	$228K	Sell	30,825 -1,529	-5%	-$8.1K	0.02%	323
2025 Q2	$146K	Buy	32,354 +20,031	+163%	+$89.3K	0.01%	336
2025 Q1	$57.2K	Sell	12,323 -704	-5%	-$4.32K	0.01%	409
2024 Q4	$90.4K	Buy	+13,027	New	+$97.8K	0.01%	407
2023 Q4	–	Sell	-1,280	Closed	-$6.13K	–	450
2023 Q3	$6.13K	Buy	1,280 +633	+98%	+$4.08K	﹤0.01%	379
2023 Q2	$4.43K	Sell	647 -9	-1%	-$58	﹤0.01%	382
2023 Q1	$5.11K	Buy	656 +164	+33%	+$1.14K	﹤0.01%	364
2022 Q4	$3.74K	Buy	492 +55	+13%	+$458	﹤0.01%	331
2022 Q3	$4K	Buy	+437	New	+$4.01K	﹤0.01%	298

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

China Universal Asset Management Company's GLUE Position: Q2 2026 in Review

China Universal Asset Management Company increased its Monte Rosa Therapeutics (GLUE) stake by 11% in Q2 2026, buying an estimated $28.6K and bringing the position to 15,045 shares worth $364K. The position accounts for 0.02% of the portfolio, ranked #292.

China Universal Asset Management Company first reported a position in GLUE in Q3 2022 and has held it in 12 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

China Universal Asset Management Company held 15,045 shares of Monte Rosa Therapeutics worth $364K as of Q2 2026.
China Universal Asset Management Company bought 1,515 Monte Rosa Therapeutics shares in Q2 2026, an estimated $28.6K.
Monte Rosa Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #292 holding.
China Universal Asset Management Company first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 12 quarters since.
192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.